Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)

Investigator: Jorge Darcourt, MD

Study Coordinator: Syed Muhammad Saad

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT03410693

Phone: 281.276.5263

Protocol Number: Pro00019585

Description

This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have received Prior platinum-containing chemotherapy.
More to Explore